Innovent Biologics Inc. has announced that seven of its innovative drugs, including a new indication for TYVYT® (sintilimab injection) and first-time inclusions of SYCUME® (teprotumumab N01 injection), Limertinib, Dupert® (fulzerasib), DOVBLERON® (taletrectinib), Retsevmo® (selpercatinib), and Jaypirca® (pirtobrutinib), have been included in China's updated 2025 National Reimbursement Drug List (NRDL). The updated NRDL will take effect from January 1, 2026, expanding patient access and affordability for these therapies, which target oncology and cardiovascular/metabolic diseases among other indications.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251207-11947161), on December 07, 2025, and is solely responsible for the information contained therein.